About IPSEN SA SPONS ADR EA REPR 0.25 ORD Company

Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. It operates through the following segments: Specialty Care. The Specialty Care segment focuses on oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and rare diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.